ESR1 and breast cancer: Studies have reported that inhibitors for epigenetic modifications, such as DNA methyltransferase inhibitors, histone deacetylase inhibitors (HDACi) and EZH2 inhibitors (EZH2i), could reactivate ERα expression in basal-like breast cancer [57–59].